Abstract
Tamoxifen is widely used as adjuvant therapy for postmenopausal breast cancer patients with positive estrogen receptors. Data on a possible association of endometrial pathologies with tamoxifen treatment have been accumulating. In this review, we examine the current literature and include our own experience with this occurrence. We recommend close supervision of these patients.
MeSH terms
-
Breast / drug effects*
-
Breast / pathology
-
Breast Neoplasms / drug therapy
-
Clinical Trials as Topic
-
Endometrial Hyperplasia / chemically induced*
-
Endometrial Hyperplasia / diagnostic imaging
-
Endometrial Hyperplasia / pathology
-
Endometrial Neoplasms / chemically induced*
-
Endometrial Neoplasms / diagnostic imaging
-
Endometrial Neoplasms / pathology
-
Endometriosis / chemically induced*
-
Endometriosis / diagnostic imaging
-
Endometriosis / pathology
-
Endometrium / drug effects*
-
Endometrium / pathology
-
Female
-
Follow-Up Studies
-
Humans
-
Postmenopause*
-
Tamoxifen / adverse effects*
-
Tamoxifen / pharmacology*
-
Tamoxifen / therapeutic use
-
Time Factors
-
Ultrasonography